PRTA
NASDAQ · Biotechnology
Prothena Corp Plc
$9.09
+0.36 (+4.12%)
Financial Highlights (FY 2026)
Revenue
133.27M
Net Income
-120,605,745
Gross Margin
—
Profit Margin
-90.5%
Rev Growth
-12.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 66.9% | 66.9% |
| Operating Margin | -114.4% | -102.9% | -17.7% | -18.1% |
| Profit Margin | -90.5% | -86.0% | -16.3% | -12.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 133.27M | 152.02M | 162.70M | 132.11M |
| Gross Profit | — | — | 108.91M | 88.43M |
| Operating Income | -152,410,889 | -156,461,503 | -28,741,203 | -23,889,033 |
| Net Income | -120,605,745 | -123,811,076 | -26,550,677 | -16,869,914 |
| Gross Margin | — | — | 66.9% | 66.9% |
| Operating Margin | -114.4% | -102.9% | -17.7% | -18.1% |
| Profit Margin | -90.5% | -86.0% | -16.3% | -12.8% |
| Rev Growth | -12.3% | -12.3% | +13.5% | +18.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 103.68M | 102.66M |
| Total Equity | — | — | 280.84M | 243.54M |
| D/E Ratio | — | — | 0.37 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -151,708,942 | -164,393,173 | -39,466,979 | -33,822,388 |
| Free Cash Flow | — | — | -19,760,246 | -19,201,664 |